


RCE/1642
JFW
+

BAKER BOTTS LLP



REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.
See The American Inventors Protection Act of 1999 (AIPA).

Application Number	09/633,034
Filing Date	August 4, 2000
First Named Inventor	Tsang
Group Art Unit	1642
Examiner Name	Helms, L.R.
Attorney Docket Number	33081-R (072771.0106)

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

1. Submission required under 37 C.F.R. § 1.114

- a. ☐ Previously submitted
 - i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on _____
(Any unentered amendment(s) referred to above will be entered).
 - ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
 - iii. ☐ Other _____
- b. ☒ Enclosed
 - i. ☒ Amendment/Reply
 - ii. ☒ Affidavit(s)/Declaration(s)
 - iii. ☐ Information Disclosure Statement (IDS)
 - iv. ☐ Other copies of deposit receipts and previous response.

2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required)
- b. ☐ Other _____

3. Fees

The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 02-4377
 - i. ☒ RCE fee required under 37 C.F.R. § 1.17(e)
 - ii. ☒ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)
 - iii. ☒ Other Any additional charges under 37 CFR 1.16 and 1.117
- b. ☐ Check in the amount of \$ _____ enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Lisa B. Kole	Registration No. (Attorney/Agent)	35,225
Signature		Date	November 5, 2004

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop: RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Name (Print/Type)	Lisa B. Kole	Date	November 5, 2004
Signature			

11/12/2004 CNGUYEN 00000023 024377 09633034

01 FC:2801 395.00 DA



A33081-R 072771.0106

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Tsang et al.

Serial No.: 09/633,034

Examiner: Helms, L.R..

Filed : August 4, 2000

Group Art Unit: 1642

For : MONOCLONAL ANTIBODIES AGAINST HUMAN COLON
CARCINOMA-ASSOCIATED ANTIGENS AND USES THEREFOR

RESPONSE

I hereby certify that this paper is being deposited on 11/05/04 with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450

Lisa B. Kole

Attorney Name

Signature

35,225

PTO Registration No.

11/05/04

Date of Signature

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
MAIL STOP RCE

Sir:

In response to the Final Official Action dated May 7, 2004, please consider the following amendments and remarks. Applicants submit herewith (1) a Petition to Extend Time for a period of three months, up to and including Monday, November 8, 2004; (2) a Request for Continued Examination; (3) copies of the International Forms relating to the deposit of hybridomas PCA 31.1 and PCA 33.28 (Exhibits A and B, respectively); (4) a Declaration Of Dr. Myron Arlen (Exhibit C); (5) a revised Reissue Declaration, with separate copies executed by inventor Arlen and Assignee; (6) a Reissue Declaration By Assignee; and (7) a copy of the entire response filed August 26, 2003, with confidential information redacted (Exhibit D).